Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Smaller size of Abbott's Xience V

This article was originally published in Clinica

Executive Summary

Abbott has CE marked a 2.25mm version of its Xience V drug-eluting stent (DES). The smaller size of the everolimus-eluting device should broaden the range of patients that can be treated, as it can be used to prop open smaller vessels than would previously have been candidates for stenting. The Abbott Park, Illinois firm claims that 30-40% of coronary artery disease lesions occur in vessels equal to or less than 2.5mm in diameter. In addition to the 2.25mm size, Xience V is available in stent diameters of 2.5, 2.75, 3.0, 3.5 and 4.0mm. Abbott is to launch the new form of the stent in Europe, as well as in selected countries in Asia and Latin America, immediately.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046491

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel